Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer No significant financial relationships to disclose. This is an ASCO Meeting ...
A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results